Tipping the balance between good and evil: aberrant 14-3-3ζ expression drives oncogenic TGF-β signaling in metastatic breast cancers
Transforming growth factor beta (TGF-β) readily suppresses the development of early-stage breast cancers, an activity that gives way to tumor promotion in their late-stage counterparts. The molecular mechanisms underlying this mysterious switch in TGF-β function remain murky. In addressing this conundrum, Xu et al. observed aberrant 14-3-3ζ expression to prevent the formation of tumor-suppressive Smad2/3:p53 complexes, while simultaneously driving the generation of oncogenic Smad2/3:Gli2 complexes. Once formed, Smad2/3:Gli2 complexes stimulate the expression of parathyroid hormone-related protein necessary for breast ca...
Source: Breast Cancer Research - July 11, 2015 Category: Cancer & Oncology Authors: Chevaun MorrisonWilliam Schiemann Source Type: research
Mammographic density and breast cancer in women from high risk families
In this study, we compared MD in BRCA1/2 mutation carriers and non-carriers from BRCA1/2 mutation-positive families and investigated the association between MD and BC among BRCA1/2 mutation carriers per type of mutation and tumor subtype.
Methods:
The study was carried out in 1039 female members of BRCA1 and BRCA2 mutation-positive families followed at 16 Spanish Genetic Counseling Units. Participants’ density was scored retrospectively from available mammograms by a single blinded radiologist using a 5-category scale (75 %). In BC cases, we selected mammograms taken prior to diagnosis or from the contralateral breast, w...
Source: Breast Cancer Research - July 11, 2015 Category: Cancer & Oncology Authors: Teresa Ramón y CajalIsabel ChirivellaJosefa MirandaAlexandre TeuleÁngel IzquierdoJudith BalmañaAna Sánchez-HerasGemma LlortDavid FisasVirginia LopeElena Hernández-AgudoMaría Juan-FitaIsabel TenaLuis RoblesCarmen Guillén-PoncePedro Pérez-SeguraMari Source Type: research
Lobular breast cancer series: imaging
The limitations of mammography in the detection and evaluation of invasive lobular carcinoma (ILC) have long been recognized, presenting real clinical challenges in treatment planning for these tumors. However, advances in mammography, ultrasound, and magnetic resonance imaging present opportunities to improve the diagnosis and preoperative assessment of ILC. The evidence supporting the performance of each imaging modality will be reviewed, specifically as it relates to the pathology of ILC and its subtypes. Further, we will discuss emerging technologies that may be employed to enhance the detection rate and ultimately res...
Source: Breast Cancer Research - July 11, 2015 Category: Cancer & Oncology Authors: Karen JohnsonDeba SarmaE Hwang Source Type: research
Can the breast screening appointment be used to provide risk assessment and prevention advice?
Breast cancer risk is continuing to increase across all societies with rates in countries with traditionally lower risks catching up with the higher rates in the Western world. Although cure rates from breast cancer have continued to improve such that absolute numbers of breast cancer deaths have dropped in many countries despite rising incidence, only some of this can be ascribed to screening with mammography, and debates over the true value of population-based screening continue. As such, enthusiasm for risk-stratified screening is gaining momentum. Guidelines in a number of countries already suggest more frequent screen...
Source: Breast Cancer Research - July 9, 2015 Category: Cancer & Oncology Authors: D. EvansAnthony Howell Source Type: research
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance
Conclusion:
These studies identify nuclear bFGF as a protein in a subset of TN breast cancers that likely contributes to drug resistance following standard chemotherapy treatment. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 4, 2015 Category: Cancer & Oncology Authors: Shenduo LiSturgis PayneFang WangPeter ClausZuowei SuJeffrey GrothJoseph GeradtsGustaaf de RidderRebeca AlvarezPaul MarcomSalvatore PizzoRobin Bachelder Source Type: research
Reduced proliferation in breast cancer cells contacting the neighboring adipocytes in human breast cancer tissues
No description available (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 2, 2015 Category: Cancer & Oncology Authors: Han RyuHan-Byoel LeeWonshik HanDong-Young NohHyeong-Gon Moon Source Type: research
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
IntroductionArthralgia is a common toxicity among women taking aromatase inhibitors (AIs) and can lead to premature discontinuation of therapy. We evaluated the association between arthralgia, co-morbid fatigue/insomnia and inflammatory biomarkers among women taking AIs.
Methods:
Women taking AIs for early stage breast cancer completed a modified version of the Brief Pain Inventory, the Brief Fatigue Inventory, the Insomnia Severity Index, and provided blood samples for simultaneous assessment of 34 inflammatory biomarkers using a Luminex kit. Two-sided t-tests were used to compare inflammatory biomarker concentrations for...
Source: Breast Cancer Research - June 28, 2015 Category: Cancer & Oncology Authors: Joshua BaumlLu ChenJinbo ChenJean BoyerMichael KalosSusan LiAngela DeMicheleJun Mao Source Type: research
Metformin in breast cancer - an evolving mystery
This study represents an important step forward in establishing one of several possible mechanisms for metformin, information that will be useful in determining candidate biomarkers to evaluate in large clinical trials of metformin, such as the ongoing NCIC CTG MA.32 trial of adjuvant metformin. The potential significance of these data for metformin in the treatment of breast cancer is discussed here. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 26, 2015 Category: Cancer & Oncology Authors: Laura CamachoAtreyi DasguptaSao Jiralerspong Source Type: research
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2 + breast cancer cells by inducing Bim
Conclusions:
PTK6 downregulation induces apoptosis of Lapatinib-resistant Her2
+
breast cancer cells by enhancing Bim expression via p38 activation. As Bim expression is a critical biomarker for response to many targeted therapies, PTK6 inhibition may offer a therapeutic approach to treating patients with Her2 targeted therapy-resistant breast cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 19, 2015 Category: Cancer & Oncology Authors: Sun ParkKoichi ItoWilliam OlcottIgor KatsyvGwyneth Halstead-NusslochHanna Irie Source Type: research
Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits
Conclusions:
The derivation of global miRNA expression profiles for the different mammary subpopulations provides a comprehensive resource for understanding the interplay between miRNA networks and target gene expression. These data have highlighted lineage-specific miRNAs and potential miRNA-mRNA networks, some of which are disrupted in neoplasia. Furthermore, our findings suggest that key developmental miRNAs are regulated by global changes in histone modification, thus linking the mammary epigenome with genome-wide changes in the expression of genes and miRNAs. Comparative miRNA signature analyses between normal breast ...
Source: Breast Cancer Research - June 18, 2015 Category: Cancer & Oncology Authors: Bhupinder PalYunshun ChenAndrew BertYifang HuJulie SheridanTamara BeckWei ShiKeith SatterleyPaul JamiesonGregory GoodallGeoffrey LindemanGordon SmythJane Visvader Source Type: research
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast
This article will review the current landscape of genomic alterations in ductal carcinoma in situ and their potential as prognostic biomarkers together with the technologies used to define these. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 16, 2015 Category: Cancer & Oncology Authors: Jia-Min PangKylie GorringeStephen WongAlexander DobrovicIan CampbellStephen Fox Source Type: research
MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene
Conclusions:
These studies elucidate a new layer of regulation in the PI3K/AKT/mTOR pathway with relevance to mammary development and tumour progression and identify miR-184 as a putative breast tumour suppressor. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 13, 2015 Category: Cancer & Oncology Authors: Yu PhuaAkira NguyenDaniel RodenBenjamin ElsworthNiantao DengIva NikolicJessica YangAndrea McfarlandRoslin RussellWarren KaplanMark CowleyRadhika NairElena ZotenkoSandra O¿TooleShi-xiong TanDavid JamesSusan ClarkHosein Kouros-MehrAlexander Swarbrick Source Type: research
nab-Paclitaxel dose and schedule in breast cancer
nab-Paclitaxel is approved for the treatment of metastatic breast cancer on an every-3-week schedule based on positive findings from a pivotal phase III trial in which nab-paclitaxel 260 mg/m2 every 3 weeks was superior to solvent-based paclitaxel 175 mg/m2 every 3 weeks for the primary endpoint of overall response rate (33 % vs 19 %; P = 0.001). Subsequently, a number of trials have examined different schedules, doses, and combinations in efforts to optimize nab-paclitaxel-based therapy for metastatic and early-stage breast cancer. The goal of this review is to evaluate the clinical experiences to date with nab-...
Source: Breast Cancer Research - June 12, 2015 Category: Cancer & Oncology Authors: Miguel Martín Source Type: research
CD24 + cells fuel rapid tumor growth and display high metastatic capacity
Conclusion:
CD24
+
cells account for heterogeneity in mammary tumors. CD24 expression at early stages of the cancer process is an indication of a highly invasive tumor. However, CD24 is not a suitable therapeutic target; instead we suggest here new potential targets accounting for early differentiated cancer cells tumorigenic capacity. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 4, 2015 Category: Cancer & Oncology Authors: Ran RostokerSagi AbelsonInna GenkinSarit Ben-ShmuelRavi SachidanandamEyal ScheinmanKeren Bitton-WormsZila OrrAvishay CaspiMaty TzukermanDerek LeRoith Source Type: research
Identification of two novel Mammographic Density loci at 6Q25.1
Conclusion:
We identified two novel MD loci at 6q25.1. These findings underscore the importance of 6q25.1 as susceptibility region and provide more insight into the mechanisms through which MD influences breast cancer risk. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 3, 2015 Category: Cancer & Oncology Authors: Judith BrandJingmei LiKeith HumphreysRobert KarlssonMikael ErikssonEmma IvanssonPer HallKamila Czene Source Type: research
